Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Publication | Closed Access

DOI

Citations

References

2016

Year

Dimitriοs Mavroudis, Alexios Matikas, N. Malamos, Pavlos Papakotoulas, Stylianos Kakolyris, Ioannis Boukovinas, A. Athanasiadis, Nikolaos Kentepozidis, N. Ziras, Panagiotis Katsaounis,

Annals of Oncology

Breast OncologyOncologyDocetaxel Versus DocetaxelClinical TrialsGynecologyAdjuvant ChemotherapyBreast CancerPharmacotherapyCancer TreatmentDose-dense FecMedicineCancer Research